Your browser doesn't support javascript.
loading
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien, Anne-Sophie; Fauriat, Cyril; Orlanducci, Florence; Rey, Jerome; Borg, Gaelle Bouvier; Gautherot, Emmanuel; Granjeaud, Samuel; Demerle, Clemence; Hamel, Jean-François; Cerwenka, Adelheid; von Strandmann, Elke Pogge; Ifrah, Norbert; Lacombe, Catherine; Cornillet-Lefebvre, Pascale; Delaunay, Jacques; Toubert, Antoine; Arnoulet, Christine; Vey, Norbert; Olive, Daniel.
Afiliación
  • Chretien AS; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
  • Fauriat C; Immunomonitoring Platform, Institut Paoli-Calmettes, Marseille, France.
  • Orlanducci F; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
  • Rey J; Immunomonitoring Platform, Institut Paoli-Calmettes, Marseille, France.
  • Borg GB; Immunomonitoring Platform, Institut Paoli-Calmettes, Marseille, France.
  • Gautherot E; Hematology Department, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
  • Granjeaud S; Beckman Coulter Immunotech, Marseille, France.
  • Demerle C; Beckman Coulter Immunotech, Marseille, France.
  • Hamel JF; Systems Biology Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
  • Cerwenka A; Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
  • von Strandmann EP; Immunomonitoring Platform, Institut Paoli-Calmettes, Marseille, France.
  • Ifrah N; Biostatistics and Methodology Department, CHU Angers, Angers, France.
  • Lacombe C; Innate Immunity Group, German Cancer Research Center, Heidelberg, Germany.
  • Cornillet-Lefebvre P; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • Delaunay J; Clinic for Hematology, Oncology and Immunology, Experimental Tumor Research, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany.
  • Toubert A; Hematology Department, CHU Angers, Angers, France.
  • Arnoulet C; GOELAMStheque, FILO French Innovative Leukemia Organization, Cochin Hospital, APHP, Paris, France.
  • Vey N; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Reims, Reims, France.
  • Olive D; Service d'Hématologie, Centre Catherine de Sienne, Nantes, France.
Oncotarget ; 10(52): 5493, 2019 Sep 10.
Article en En | MEDLINE | ID: mdl-31534634
ABSTRACT
[This corrects the article DOI 10.18632/oncotarget.17747.].
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article País de afiliación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article País de afiliación: Francia